Results from a Phase II study show that pasireotide effectively controls GH and IGF-1 levels in patients with de novo or persistent/recurrent acromegaly, and significantly reduces pituitary tumor volume [69,110,111]. This evidence concerns the gene GH1 and pituitary tumor.